MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

Home・Akciju saraksts・AnaptysBio Inc

AnaptysBio Inc

Slēgts

SektorsVeselības aprūpe

68.49 4.89

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

63.88

Max

Galvenie mērījumi
By Trading Economics
Ienākumi	35M 50M
Pārdošana	32M 108M
Peļņas marža	45.833
Darbinieki	104
EBITDA	29M 68M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+26.98% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 1. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	259M 1.8B
Iepriekšējā atvēršanas cena	63.6
Iepriekšējā slēgšanas cena	68.49

Ziņu noskaņojums

By Acuity

47%

53%

158 / 348 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

19.25 / 21.135 Atbalsts un pretestība

AnaptysBio Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB: Higher Energy Prices to Raise Production, Consumer Costs

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

2026. g. 10. apr. 00:00 UTC

Galvenie ziņu notikumi

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

2026. g. 9. apr. 23:44 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

2026. g. 9. apr. 23:34 UTC

Tirgus saruna

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

2026. g. 9. apr. 23:14 UTC

Tirgus saruna

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

2026. g. 9. apr. 23:14 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 9. apr. 23:07 UTC

Tirgus saruna

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

2026. g. 9. apr. 22:54 UTC

Tirgus saruna

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

2026. g. 9. apr. 22:31 UTC

Galvenie ziņu notikumi

Trump on Truth Social: 'That Is Not the Agreement We Have!'

2026. g. 9. apr. 22:31 UTC

Galvenie ziņu notikumi

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

2026. g. 9. apr. 20:57 UTC

Galvenie ziņu notikumi

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

2026. g. 9. apr. 20:55 UTC

Peļņas

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

2026. g. 9. apr. 20:55 UTC

Peļņas

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

2026. g. 9. apr. 20:55 UTC

Peļņas

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

2026. g. 9. apr. 20:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 9. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 9. apr. 20:40 UTC

Iegādes, apvienošanās, pārņemšana

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

2026. g. 9. apr. 20:39 UTC

Iegādes, apvienošanās, pārņemšana

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

2026. g. 9. apr. 20:39 UTC

Iegādes, apvienošanās, pārņemšana

Rowan Digital Infrastructure Announces Strategic Recapitalization

2026. g. 9. apr. 20:25 UTC

Iegādes, apvienošanās, pārņemšana

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

2026. g. 9. apr. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 9. apr. 19:30 UTC

Galvenie ziņu notikumi

How Digital Currencies Have Helped Iran -- WSJ

Salīdzinājums

Cenas izmaiņa

AnaptysBio Inc Prognoze

Cenas mērķis

By TipRanks

26.98% augšup

Prognoze 12 mēnešiem

Vidējais 83.22 USD 26.98%

Augstākais 140 USD

Zemākais 50 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi AnaptysBio Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

10 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 10 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam AnaptysBio Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

19.25 / 21.135Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Noskaņojums

By Acuity

158 / 348 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.